AbbVie’s ADCs are designed to target unique protein biomarkers such as c-Met (MET protein) and SEZ6 (seizure-related homolog 6 protein).

Key ASCO updates include the following ADCs:

• ABBV-400: A Phase 1 study in heavily pre-treated metastatic CRC patients revealed new safety and efficacy data for ABBV-400, a next-generation, potential best-in-class c-Met directed ADC.
• ABBV-706: Data from a first-in-human study of ABBV-706, a potential best-in-class SEZ6 directed ADC, in SCLC, high-grade CNS tumors and high-grade neuroendocrine neoplasms (NENs).
• Telisotuzumab vedotin (Teliso-V): Data from the primary analysis of the Phase 2 LUMINOSITY trial evaluating Telisotuzumab vedotin (Teliso-V), a potential first-in-class c-Met directed ADC, in advanced NSCLC